Monopar Therapeutics (MNPR) EBT Growth (3y) (2020 - 2026)
Monopar Therapeutics (MNPR) EBT Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.22% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 12.16% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 86.16% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 41.79% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 95.61% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -38.56% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 38.36% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 64.03% |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | -33.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -33.33% |
| Sep 30, 2025 | -20.99% |
| Jun 30, 2025 | 3.27% |
| Mar 31, 2025 | -9.38% |
| Sep 30, 2024 | 15.65% |
| Jun 30, 2024 | 5.13% |
| Mar 31, 2024 | 3.47% |
| Sep 30, 2023 | -5.84% |
| Jun 30, 2023 | -17.06% |
| Mar 31, 2023 | -29.92% |
| Dec 31, 2022 | -52.38% |
| Sep 30, 2022 | -46.48% |
| Jun 30, 2022 | -44.33% |
| Mar 31, 2022 | -19.85% |
| Dec 31, 2021 | -58.40% |
| Sep 30, 2021 | -53.86% |
| Jun 30, 2021 | -45.26% |
| Mar 31, 2021 | -27.23% |
| Dec 31, 2020 | -62.67% |
| Sep 30, 2020 | 52.00% |